Sanofi Agrees to Pay Up to $8 Billion for Expanded Long-Acting Drug Pipeline
French pharmaceutical company Sanofi has entered into a deal worth up to $8 billion with Regeneron, including an upfront payment of $1 billion. The agreement aims to expand Sanofi's pipeline in long-acting drugs through joint development efforts. The news initially caused shares of Sanofi (SNY) to rise by 3.6% before settling at a more modest gain of 1%. Regeneron, on the other hand, saw its stock price increase as well due to positive market sentiment surrounding the deal's potential for innovation and revenue growth. The partnership is expected to leverage both companies' strengths in drug development and commercialization, potentially leading to new therapeutic options with longer durations of action. This could position Sanofi more competitively within the pharmaceutical sector.
Topics: M&A & Partnerships Pharmaceuticals